Endgame with Gita Wirjawan - "Gene Hunter" Prof. Herawati Sudoyo: Sains Tak Mengenal Batas

Episode Date: December 16, 2020

Teknologi, terutama di bidang biologi molekuler, berpeluang memberi kita kuasa penuh atas gen dan otak kita. Bila itu terjadi, apa kelak artinya menjadi orang Indonesia atau bahkan manusia? Perbincangan dengan Profesor Herawati Sudoyo, Deputi Bidang Riset Fundamental Lembaga Eijkman.

How much of the we have to a fragment of DNA from the mackleuk line to a factor or whatever that can be able to put in their own. Creating something which is different, that's the question

then, and then, and now, are we playing God? Yeah. This is Endgame. Hello, Hello, my name is today we're coming Professor Hera Sudoyo,

ahele molecular biology, and also one of the founder of Aikman Institute. Buera, thank you, atas the coming. Thank you, all of all of all I'm very I'm very

here to discuss, or maybe, or talk, or binkang-bing-bing-and-cang-cang-cust- -a-tank- Thank you, I'm going to start with the child of my

you, you're from here, and from the life of your life of you, it's, tuntunuching, from U.I, then to Australia. Silakan, Buk, be it's about, I'm going to be in Kediri. Because for the Paray, it's insult, if they're saying, he'd like in Kediri.

Parre, is the Kota Ketamatan, small, and Kediri is more. So, Parra, it's really, so far away, it's a part of the city that has a story. So, it is a place where, where the people

of the old, colonial, that's the area of the perkebunan. He has a room of a great I'm very good. I was there, because I was because my dad's my father is military. And, when I was born,

he was being in other so, so, so, I was I was in Paray. Now, if we say, if we're going to be paris, I'm actually actually, I'm actually also in the other, because a

an anthropologist America, Cleaver Kyrhers, it's really, it's about the book of Javan, about people about prioryi and to Javan, like that. So I think, oh, okay, I'm like, I'm in the city that I'm actually, I'm actually,

and it's also to about about the other who don't know, because they're saying, pari, pari, that's in Sulawesi, I'm, I'm, really, you know, you're really, better, I'm really, have to learn the world, that's, that.

Pindh, to Jakarta, is? Now, Then, we'd, then, we'd, I'm back, from Bandung, from, to Jakarta.

And in Jakarta, I'm at the school at a Catholic. Because at that, Mewa... Inda because of the PENUGASAN. Okay, so... So, yeah, as a person military,

I'm going to go to anywhere my father I'm going. Yeah, we also, I'm going, too, so, that, so. So, that,

then I, from, Well, of the school in the school of school, I'm from school that's discipline and everything, so I'm going to be in school in the school, even though he's quite well, he's quite the kind of, because I'm thinking that in school that is good, or not,

a person, it's not, it's just to be it's puttack to to be in the school of Catholic, we're really, bethue to dole-dochre all of it, how efficiency of time, the way of learning, and sogain. Now, I think, if I'm just-terusan in Catholic this, that's full in discipline, I'm not going to survive,

fact I'm a masypacif, because I can't try not I'm not so I'm going to tell you I'm going to go to go to school in the country I'm agate they're because yeah, yeah, it's a bit better. Semawyeriae, but yeah okay, like that's it. So that's the story.

So, it's all of the people's on to beputusan Wow. When, when, Buk, when you're going to be with the doctorate? Now, if you're juster, yeah, I, too, I like, the thing that's the school in Bandung. I think I'm being a architect. Because I see that, there, someone can be able to develop

and then the ideas, innovation, the innovation, it's more more than than the other school that's the other there's two. We're,

we're being a doctor or to be a engineer at that so, so, because, because

the of the administration, so there report that who's not come to meet, I can't get into the ITB. So, then, I'm testing for the U.I. and the priority first

for the faculties of the doctorate. But, that, what I see actually is this, this, institute landscape from Tresacti. I was also to there. Then, the Institute Textile in Bandung.

So, it's actually to be there. Just because, because it's not be able to get and so again, in Jakarta. And, because, there's a deshackan there's a desacan of ourga. There's one doctor in the community of our big

and then, oh, Herr, that's, book of the book of my, that's about you can I can't give you to me, anatomy. That's a book that's like Bible from the faculty of doctorate, that's import, the time and many books, and many books other, that's really,

that's really, that's really, that's really, that's really. That's the story. Then, yeah, I mean, yeah, I was at the faculty of the doctorate, I'm from there. Oh, big. But from the SMA, it, is it's a hobby, with class that's

that you're in along with the education? No. I'm probably, because I'm nerd, I'm more like to be reading. I'm from school, I'm going to be I'm not just about I'd like that. So, so I'm just routine. Okay.

From from the first, from the first I'm not. So, yeah, I'm not. Okay. Now, then, then, I'm from the Faculty of the Doctorate, yeah, Bue, yeah? Yeah.

Okay. How, ma'am. Lulose from Faculty to Doctorate, it's just two All right people who want want to want their if they're going to want to the one of the bigot-bearing

that is the part of the children of bedh or or penickeed-down I, I'm a student who's had been a house-tangue,

so I'm I was a little bit of a class of doctorate. So I'm a doctorate. So he's the most of the mostiness, you're going to be able to specialization that. The most of my time was that was, that he will be more in the other room

and I'm in the other, I'm in there in the other, medidic the kids, so I'm, so I've made a role I'm,

as a woman, as a person, as a person, house, uh, the, um, Now, then what's going to be?

To where I'll be, I'm going to be able to be in the staff the teacher of the doctorate in Indonesia in the body of the doctorate. That's the termed preclinic. Preclinic, what? It's not he that's who that's who's who's who that's who are with, with patients.

Now, this is interesting. Because if we get into the the endang it's the endanguechang is that we have to be a quesuosusan. So we have

must, make master or even to make doctor in the more than the other than more than more than that.

So, it's just the path of the way that. So I'm taking master in the FKUI. And I've got a baby again, so, okay, he's still so, while having two of the two of the children, while they're doing the two of the school, then, then, they can't be there.

It's been to be the doctor. Now, I'm getting a question to the doctor. I'm getting a patawarant to take the S-3 at Monash University, Melbourne. They're keros.

I'm a one generation first from the University of the University of from the University in the year's 70s or 80s? In the 80s? In the 80s? So I and the friends who Indonesia is is a clinchie percied percied.

If we're going to be able, it will be open for Indonesia. If we're not, it will be able to be it, because they're very competitive, yeah. Yeah, yeah, better. School is good. So, okay, in fact, six-bunarget from school,

that's the family can't be brought. But, but, there's not there's not the other than the or the other thing that's just to one of positive, if for me. Yeah.

Stress too, yeah, no, no other than the other than I'm because I'm, I'm going to be able to, and after I'm looking that I've got adaptation with the linguanguans and sogain then my son I can't, I'm going to take I brought in the time three-bun-malan. So two of my kids are, I quote, that is that's how

as a woman, a person, yeah, all of all, sopire, mass, all of, but still, but also,

that I have to do as single mother, so for five years. Wow. With the best of the other, musty-you-dochurcha-schools other, not only from Australia just. Why, to Australia?

Because there's a panangance that molecular biology in Monash that's the right for endgame of it. No, at the time that was the biology melchul is something new. Recommendant DNA is still debate on the pro and contra, so. So, so.

So, whatever even actually, the project penelitian, it's not going to be a problem. Now, that's also that I've learned, that's what I'm saying, is about about focus, or topic we're doing, it's as well as to be it's as well as a matter of,

for, like, national, or the importance of, or the importance of, not. Because S-3, doctor, that we still learn, right, but we're, really, we're, that's all that's still supervise. Post-Doc, that's what we're

What we're actually, just to be there be of a individual, and then, innovation, to be it inovacus, to be able to be able to be a manipin, so, I think, oh, okay, I think project,

that's not been a problem, or is, is a project that is something that's very very, that's very, that, I'm, I'm, with a certain from the children to the and this is a genetic that's very, yeah, in the same that.

Detects, or diagnosis, it's used to DNA. DNA, that's, the time, too, is, it's still, it's not, um, it's not, uh, but, but for me, what I'm the important is that In the study, we can't know the project and troubleshooting.

So, what I mean, the brain is to be made, so that it's really coping, with problems problems that there. Just to, if I'm still, I'm doing work for help, I'm going to, I'm not, I'm, not learn whatever, because it's too easy, yeah, too much.

That's, so much, that's, so, that's, so, got program doctor, and then, then, comealy. Now, but, one of the key,

actually, yeah, which, so, Also, that's all that's all of that's that's that's not that's not from the end-up the place we're being built. Because it's good for the jarring.

So, there's a place where we can take technology that maybe there's a more because I was in the technology sequencing, it's just out. Now, in lab we have one company, it's the community that's the company that's known, America, that's put the other, to try, to try. So we have five, PhD students, that's what, that's that's trying to make the

carat-carat is to leleh, because of the we're using it, so there's a lot, we're trying to try, so we're in the method, the technology that's the use, the world, this. So, I think, the experiences like that, that's to be able to be made up.

Curiosity's why Australia? Because it's almost in the 80s, where the other than other than it's quite, that's quite, that's, can't. America. America, system is, schooled-dulled-dulled-dust,

then, research. Australia, Commonwealth, it's by research, So, that's the other. I'm trying the other, university, that's

using the English. Because if I'm using other, it's that's double burden, too. I must be in in a certain and a work and a new

same as well. And then, I'm also, I'm also I'm not even with the same of the Australia that's one of the things part of the other thing that. The other is that's scouting that.

So Monez, Department of Biochemistry, it's... ...punia, ...that's a professor Sankop Marzuki, who's actually, FKUI, but thener he's in there. So, so he's got to be taken to staff. Now, he'll,

so long that, always with a ma'asusual Australia. And at a certain time, where he's made that, okay, I've got with students, students, student, Ootrali, and how much

to back it to Indonesia. So, that's, That's like, they're scouting in Thailand, because he's also school in Thailand, and also, and scouting in Indonesia. And I'm... And with her, she was the founder of Eichmann. Yeah. Okay.

Tell me, about Eichmann. Now, okay. I mean, you're legendary. Can trace the peristriwa of 2004. Yeah, but that's one of many, that's one of many, that I'm doing. So how we're we've been developing a company that's in the biotechnology Indonesia.

Now, the, that's not bottom up, that's top down. Because what? Because, At that, the era, where biotechnology

has a priority national. Now, priority national, it's not able to build, and then, and then, people,

people, make, vaccine. It's not that know-how-y-now-now-ne-haw-y-ttina that's the to the in Indonesia,

that's basic research or research is very much and it's disadry-tack. At that, MENRI-RISEC is BGABB.

Now, to make a new a person that's better than peddoran, better than the mowspun obat

or abat-obotan, or whatever vaccine, That's the time It's time. Then, then, there's many of many people. Now, there's we're going to.

So, that's a lot of a company penelitian fundamental that he, the task is to support biotechnology

to doctorate. And, now, why, E. Why, not a company biology molecule

what, de, Sadjito, or the company biologic molecule of molecule, CIPTO, because because the the building that we use, it's

the name is EGman Institute. Dibuartesm that made the buildings bursaericata in DECA, Jakarta. That, and it that's been built by the government

Belanda, for a lot of a company penitian, the first director, Christian Ekman. Christian, the menang Nobel. Right, Christian Eichmann, made a new year 1929 for the penumannes, which made an idea, so,

always, that's the the kind of vitamin, it can't cause can't be able to cause cause by Kumae, or pathogen, like. There's, that, that's notherstic, then one factor from one factor from the

amount, it, can't make up because of a good, that's the concept that's that's what you've got had Nobel. Now, the GEDUng that, then because, in the year, it was, he took Japan, yeah? So the people who are the only people who did not have. Then, after,

in 1965, it was with a sedentiria, because crisis. After that, it's what, it's it's been a part of from, it's been used by Rubhacki-Cit-Mangun-Kusumau as a laboratory

bacteriology. Abis it, if in the place that we're not just, not just, Mati-Suri. Restec, we're saying that we have to have

a company. So, the The other is where? And then, then, the name is what the name is what the time. In fact that was a certain time in the Netherlands. Because he, then,

then, then, back to the Blanda, Christian Eichmann. So, it's been used as momentum. We have to remember 100-tahun-old Pernamon-Eckman that

in the States. Now, that's as a political, it's just to give it to be a position that EG1 this is important. So, we're using, okay, if we're revive, and make-hiducan again, a one ever there in the time colonial. of the people who are asked,

why we're in jajah, but we're using the name of the jadjazz. The answer's one's very science has no borders. Exactly. There. There. There's no science

science of my, this is science of you, and we're not We can't talk about it's not. Science is universal. So, no, there's who can't talk about what about. Oh, yeah, that's true. The second, we're with Singapore,

from the sudet science. Christan, is the director of AMCB, Institute for Molecular and Cell Biology in Singapore. He got funding from Likwanjou, almost not-batted, to buy the pletit of the world to be brought to Singapore.

It's called to be we, because it's not going to be able to be it, more much, better than in the country in the country. So they're to Singapore, they're one group. Yeah.

Not one, one, then scouting, again, no. So, Kristen, came to the company Ekman, they looked

and looked at the other, we've got to him. He said, you're very, very lucky,

that's, because he will barter, the building like glass tower, with Revelles Hotel, with in Jakarta. So that's so, okay.

What I have is Hilton. But you have is Rebels Hotel if in Singapore. So, the name that's own, it's already, it's a branding, it's branding. And this is based on the research that's done And the information, and the world, I mean, most of the people who are in biochemistry, biology, know Christian Ekman with beretri-berin. So, we, that, just sit and then,

if we're from Aitman Institute, all of them all know. Branding matters. That's branding. Not even with all the things of the things that to proclamir-can-itreting that we have a

one of the lawytheid that's named the Nobel Prize, Nobel laureate that. I like, what you said, what you said, science matters, science, doesn't have a bitas. And then, after the other, I'm much to make sure

to make sure that to make sure about more about science. That's how, that's, that, that's,

it's a provocation, so that Indonesia, to be more more than empirical science. Okay.

That, that, if I'm not it's a must, it's a must. Yeah. I'm not sure. Penelite that

has to becenduronging to not becicare. They're working in tenep. But that, I'm seeing that that pandemic is, it's just, we're just, how much, it's been from January,

like the world, world, it's just 10-bun. But it's all of all of it's been the patterned. Something that we don't want, we have to take. Something that we didn't work we have to learn to do

work. Inferii this is now it's now the hos. It'sin is it is is it is is many information,

too many information but it's not to know what's right, and what's wrong. Now, this is the case is that the people are people who are being able to be able to be able to say that it's not very, because we don't ever be learning how to make

communication science, use more than that's not many that can't. They're very much of the international seminar with penit of penit of seminars, not use using languages, all know, they're just to know. They're jago, in that in Indonesia,

Valentine's time. But, that it's been in that, okay, this, this, But I'm just to public, that this is not even, so use of the reasons of the pseuddle scientific, it's hard to talk about, because it's used in the ways of the way that for every day,

but public didn't ever mend that. So, so, now this just to, I'm looking, that many scientists in the word-bicially. Yeah. That's good, you know, I've got to beaacus about COVID-19. So,

how's it, what we have to know what we have to be about whatever, so we can be

out from this law this. I, I, I've been many many Like many of the other people, or are that also,

or other people who, who are not ever working in science? I like, because I'm from Mones, I'm monest-mongest-magnet. I'm going to, I always use. Ancora Imparo. I'm still learning. So I'm still learning. So I use that always,

that we're now, we've got to be the virus that we don't know. That's not even though, and we don't know, and every day we learn. Because that's what's what's what's the thing. So, that, information from the scientists, from the people in COVID,

that is publicasical in journal every day that's out. Now, it's kind is a certain for the other

to learn and why it must be out and it's not that people learn something that's something that

that's that before that's not been in front of what there. Now, this is a

phenomenon new, that's that's that's the time from the bank's to publication, so that's the time of the time it didn't happen to be, that people that are able to publicize without melancho review. Now, this, it's just because this

this is all of the percepatan, all of people are just to be able, the right out. Now, if they're then they'd like, if they'd, like, they'd use some of the same thing that's or a method that's even more, so long they'd be retracted,

the paper that's long as this is re-tracked paper that's new, then it's also, then, it's the dynamic from the people of the people, whether they're working, or they're making,

that's all of the world. It's really, it's a really one of the one of the world. If we look, if we're looking spectrum,

this the best case scenario, the worst case scenario for Indonesia, that's the best case scenario like, and worst case scenario like how for Indonesia or for

the world, in context COVID-19, or penangannananan the COVID-19- actually, what's not a lot of coordination but that's allurethes to include-serta. The whole-it-cote-sterta is what? The whole-it-cuit-sterta in this

the from where. They're not they're not people who are difficult, but that they're have been doing

some of things that with how to make sure to make sure they're just who they're doing without

incutsertaken matriket, both, they're just just, In one side, test we're still still, we're still, we're we're also, that what we're

doing to find, so, so it's not as a detects, then, then, then, and then, to try test contact, not as fast that we want to make. So, this is still getting-gallan, we still just still still still still still.

We still still to come to come to the other. We're still. That's not one of the other that's not one of the question that we're all that we're now. How that's the way that's that's what we're not

we think we're, or we're we're tangle-langing, it's not we can't be think of it, we've already, we've already, But, but if, if it's the other than it's there's a lot of instructions, as well as public that public is not to or not to find out of the

sumber, sumpur, so that they're to understand, what the reason we can't take a distance one meter? Why not two meters? Why not one-and-a-meter? Now, it's all of, actually, there's been, there's

there, some day-and-in-as-a-a-te-and-in-sas we give information that to the public. He will get, he will be, why, we want

you more than one-meter. Why, if, if, It's more more than you batup, the speed of how much. It's all of the upcourt. It's all of the results. But it's not just to be it

by-to-byte-to-public. Who's the wrong? Scientist, if I said, because at this they're the function. We can we've got, we look, we've got, there's many references, But why you not to give you? Kourn't be,

I'm not saying, I'm saying that's something that's wrong, right, counter that's with using, that's the reference. Yeah, yeah. Yeah. I'm, if I see,

in the nega, the country that's more than $300,000 per 1,000. If in Indonesia, of, it's much more than that. I'm still, but, testing, that must maximum. So we can't know, like, what?

Yeah, right? And we don't know, this, the, like, how much. And then, I also, I just said, that this is, this, it's not only risk of the health, but risk of information. That information,

that's not to dissemination, so-cucumnation. And that's, it's maybe, or it's been by the scientists. So, I'm going to take to the backang a bit,

you know, the B. The United of the people of the Umbudsman in the front of the Uttuania in 2004. Maybe it can be can be a little, where at that?

Yeah. Okay. People are a rome Where's what's the result of you? What's the research that? What's the penitian of the other? What we need? Or I don't know what you're doing that?

Like, not napak in the Bumi. That is all comments that we did that we'll do with a new market to look at population, to look at the people that's people that's that kind of that's very, so we've used to do with using DNA mitochondria. That's DNA that's downed from the mother to the children.

So, if we're like, we're like the same DNA mitochondria with the mother's. And all of theodera are same. Now, Ibu have DNA mitochondria that's same with the sodara, but the sodara that's not

to the children, still from hiserine. So that's that can be used to look at, actually, migraeci from the people. Mitochondrial Eve. So, we've just been

used to do that. Now, DNA, this, there's many in cell, in cell, in the cell, So if our cell, one cell, it's one, but the mitochondria's a lot more, the DNA more than more. Now, the casus perledakan, bomb-bunodir, that's, for people from Pori,

So, who's what's-dakwai-a-a-a-turd-gut-a-tred-gou-degu-deged from the person-bun-bun-a-dir-in-a-k. Because bomb-necure-out-you-lot-a-lac-cac-a-cac-old, so, there, there's a certain-tri-tri-a-k, Because too close,

then the right, the human being from the person is hangous and can'ture be beapping, there's other that's upo. Now,

for identification, that's standard. Biasanusat, and then, giki, but if gaii, in Indonesia, because they're

I think of the doctor giggins. Now, then the third is DNA. So, you know, the people, Pauli, you know, has been a mitra of Australian Federal Police who's the most deep. But for long, in there.

So they want to do something that's quick. So, okay. So they're asking for, the Lempan, can be collaborative, to be able to identify we can't even if we're in the end up, because the garringanes

if we can't if we can get can that's just like, the data that that's just we're going to take whatever even

in the in the area in the area where from the two-the-thing-and-sebrate, because it's all over, so much. And we're looking, it's not a lot, so we're going to be able to, we're only taking a big of the same, all of the DNA that's what?

What is what? Artiness, can, it's been a one person. That's. So, that's from Polri, has been over several cell that's in Jawa this, who are

responsible for terrorism. So, they're looking a pembanding. Who's the two people and the two people who are the most

is there are the mother. There's a lot. Or, if not, the sodara, the other, but but, but it's it's all right, so then we're

all right, okay. Then we're trying to make bandinginging from various kinds of cell, Jawa Barat, Jawaa, Jua Tengah and so againnial. We're so, how much

the pola they're going to because we're discussing for this. So, so, So, we know, we've got the two people who are the same the NAA with the people who are born-ne-deer-deer.

I'm sure. But the question is, if this is this one of the other one of the kids, we don't know who's who's who's who is what. Because, because, all of them are same. That, kak, ber-adig, is the DNA. So we still have to look at the DNA inti, chromosomal DNA. That's a person, a child, that's DNA,

DNA's a dayna from the father, and the half from the mother. That's all, bethutal, that's then, then, they're then, so, so, the two of the two of the two, and they're, that's, How much? 13 days.

13 days. That's one of course. That's one of course. Wow. That's about it. Wow. Wow. Yeah.

So, until the people who are you get caught? Oh, I mean, sorry, but not get-tacep, but the know what? Wow. Yeah. The most of where, where?

No, there, there. In the place. At the time, Timur, Tengar, it, that they, when there's a pletaka, there's one that's claimed. Bede if in Indonesia.

Okay. That's not being claimed. This is from the people from where, so they're making, they have to try it, so. It's very, with Timur Tengar, with Japan, with the U.K. Yeah.

I have one other, I'm not there's about the other than the other than the other than ushouns. Yeah, right? That's to more to the theory that we're diverse. Yeah, right? That I, I try to summing to the people's about people that,

We're from evolution. If we're going to the homoomonging Aristotle, that's actually, manusia, is carrier information genetica, that's downed from anyone, before we. Now that, in the context, how, how about, ma'amanae,

this is very, manoeuvres of Indonesia is very, very, because, what, look, geography just

just the geography just it's kind of the area, and the of the

other, the other barred, then there's a must land in the other than to Polynesia, and this is a part of the migration track. And, it's been used as migration track. So, of the question is, like what, what, is, like, what, is,

because there claim that that I'm not know what I'm not know what's because, you know, if Jawa Jawa said I'm not saying I'm a Indonesia, that Batak, you know, Indonesia's a geopolitic, right? Indonesia is a geopolitic, right? This is interesting. Because this is one project, I think,

that's a very relevant from, not from the sort of we look at the political, or from the sort of the doctorate of its own, the doctorate of its, if we're looking, from, okay, information genetic, so we're using many of the kinds of the populations, that genetic just, not, If we usually, we usually, holistic, holistic.

So we look at the language, we look at social buddial buddhayana. We look architecture from the rooms, because from the room it's just, we've got to see the impact of this is, or the power out of Africa, or the people who are in Arabic So that's what we use the language now.

Indonesia, it's been in four times. So there are four migrations that's what the people that's what is called Manusia Migration,

out of Africa. It's migration from the from the 16-200-200,000 years ago. It's in Indonesia that's 60,000 years ago. That's in, but that was in California,

yeah, yeah, and, all as a paparant Sunda, Sundalen. So, it's not so much for them for them from Africa to from from the Sundalen. And then,

that was, So, like that's still has still thereatheed so that's quite to the world to the world now can't be able to now. Then Sahulam,

so Papua and Australia also one too. So that's what we're left in. Okay. Then the second, there's migration that 30,000 years from the area, the Unan Kunming, astro-Asiatic,

the back 6,000 years ago from Formosa, down to the back, this is the the barasana, and the, uh, uh, the Pusca, Easter Island. The fourth, this is that was, it was it was, so, of the time one, from one, from now. This is we've got to come-asukaan,

the people of the Arab, India, and from Europe, for the trade of the rempah and all of all. So, this is all the men's Indonesia. GADUGADU. GADUGADUB-B-Bank, now, how to be it? With DNA.

Now, it's to beckon with DNA. The first is that the mitochondrial DNA can be able to look at how the person. Why chromosome will look at the way of the same? The other than the two is the same. So, really out of Africa, and then, also, the other than the journey is same. So, it's been synchron.

The other, the nuclear, so that's chromosome of DNA. The result is ad mixtures. That's what's the name is, the campuraing whatever that is, will be able to be it. This is what name, what method or technology? Whole genome sequencing.

Now, this, all of the people Indonesia, who's all genome sequencing from COVID or from SARS-2, they've got to be there, they know, they know what, whatever, that's all of it, all the sequence of it. Whole genome sequencing from the human's, that's the whole of the form of, how percent of,

and, if, then, so we'll see that from Indonesia, Indonesia-inor, to Indonesia-timur, we can see we can't distribute the of the information genetic, from the four of the then. Then, then, when it's up in Sumbah, it's

that's from Papua, the out of Africa, the first migration. The out of the way, more than more, more than to Papua. And if in Indonesia, West, more astro-Asiatic, that's the 30,000 years ago. That's the language, Kemer, Monkmer, and so, and sogain the other than Berman, sogayn. So that's actually that that's what we're

to be Indonesia. That's what I can't say that I'm moren Indonesia. Because from from... We're migrant, Batak,

to the portion of our our part of our that's different. Yeah. I'm going to push more this, this, but, if you're going to get genome sequence, that's the endyclopedia

from information genetic. There are 21,000 genes in cell. If I'm back, this is many is actually, now, practice in in other laboratories in other in other major, and also,

some of the other than in other to make it to do detect to get genome sequence. Now, this can be be able evolution that accelerated,

yeah, right, We can't believe if we can, if we can, theoretically, if you know, to make-in-a-Q, or to make-in-bidant, or to make-buhack-en-clinan to transportation oxygen that's more,

so that we can be a plari that ullung. Now, that's how, To do you look at a cut-end pace or editing to the genome sequence, we can't, okay. If I can't, actually, to the technology before it, take on the time

reqayasah genetica that's just the same with genome editing, So how we have to give them how much of the fragment of the other to a factor or whatever that can put up to be able to be able to be different. Creating something which is different.

The question is then, then, and now, are we playing God? So the recommendations DNA that's more complex than what the genome editing now. Genome editing is very much much

muddarding and it's also a one of a trombosan, where we can do therapy Tala-talesimia, that's a lot of the same thing that's which is a newfound. And that's one thing that's been perjointed, progressive, until at one of a certain, all of, it's been, because it's, because he had made transfuture, so there's deposit

of the deposit, we can't use the case, we can't get it, then, then, and then, to get it, and then, it's one of the same, it's going to be in there. Now,

we can get the information genetic to, and to make make that normal, that's the process same with the recombinant DNA that's the factor

ethical is just to here the reason is the thing, the thing, the thing, because we can do what's just just,

with with all technology we can, we can do But this, but, the process evolution, can, inter-disruptcy or ter-pengarue

by phenomena of the phenomena of the natural, or what we're doing it, right? Yeah, right? Now,

I'm like, if now, now, now, many of the major-ne-negou- to do countered

their for their to be more more-pinter, whatever. Yeah. Now, that we'll can't

or kind of or getting how do you deal with? This is very dilemmaatist, though, I'm for yeah, that's again

that's that's ethical, that's still still, so, so, so,

so, consequences for the for the people who have done it. Right, we're about what we're doing, we can't do we can't, but don't do it, but don't do it in cell that then,

that's going to get under the generation that will be it, it will be able to the tenam the generation of the I don't know this is how

it's how we can be able to that's that's not there's all that, because if it's not there's no longer, it's just jungle, this is out of the power of all of it. Now, if it's the question is, is it's a question about, is it then, will be it's going to be it. Again, it's a thing, it's.

So, from the technology, Indonesia, not going to be But from the from the point of the importance, what we need? If for therapy, where there's there's there, there

other therapy gene that we've tried that we've been over time that, it's not been a result, this is

a troughousan. If that, it's, it's It's also in the public-doctoring, in the world of the doctorate, not like in the other, we have a commissi ethics. Comission etiq is,

actually, who's really, or to look, uh, studies that that's in the way, to behawakness, yeah, in out of the way,

the way, the way, that's normal, that, if he not lullus, ethic,

and then, if I, keep, you know, consequenceinia, you can be out of, that's,

and, that, that's, and, it's, All right all of the community, it's all right, so it's been able to be. Right, rambu-ramed, that's actually that, okay, we will not do it.

But I still I'm still there are some other of some of the other than can't beableas and will beblest. Yeah. Without the name, right. Yeah, right.

And they're nothall can and meducing, in budgetary. The angharation is, it's, I don't know, the consequence of the consequences to where. Yeah, Like a conspiracy theory, there's also, there's a

a possibility that's just that's just, if, if, in case that's now this, it's just it's just to be able to beckxed it, so this is, it's not, challenge, but, yeah, if something in the out of or whatever, that's not communicated

as far as well, we know there's there's of the other that's all. If I see there are some of the major major major major that has

to have to to make the economy and that two the two of their one,

how they can to be able to beauching to be able to make sure in economy. Two, how they can beaeradaycan synthetic biology. Yeah, right? Now, it's been in Europe, barat and in the other, it's already, there's there,

to beacal. Now, that, Indonesia, how that's the kind of the stup of the the person of the posture of the biopactant. From the system of the practice in the labangam. Editing, recombinant DNA,

all have two sides. That's like a piece of armata two. So we can do it for humanuansian. We can do it for for for use. If, if we know that one of the other one individual, like, to try to, what, what, what, yeah, to keep, what,

information about one virus, one pathogen, and so again that's not going to be able to do that. I mean, it's not there's no use. Because we can, can't make a virus new, and then, also, and then, even, and they can't be able to

the human, from synthetic. That's very much, because it's just synthesize potong and then, then, then, to make one. It's just 30,000.

Manusia, can, three million, so, this, this, this, this, this, It's also. Indonesia also, oh, genome editing, there's also, so.

So, now, this, we're, we're in the era that's all technology to bea-and, it's so quick so we can't

let us that genomic, artificial intelligence, and then all, All right. Our doctorate we can't like like the time of the telemedicine and

all of the other things, it's all about in a while, it's all that's been done. And pandemic this is to speed it to be to be something that we don't or we,

actually, but we don't want anticipation. Yeah, right? We're genomic. At the time we talk about genomic, that's important for the doctorate-precision,

there's not who hear. We're like a quick-and-git-it-huh, that this is era that new, we, that, we're, to give

or therapy, penobotan, and, and, so-e-ne-e-dus-individu-per-individu. The other other data data that, data that, data clinies,

so that they're so that's quick so that's quick so that we're going to get a little if we're not to now, now, want, not,

want, not, and now, and now, and now, it's just so, if we're going to no other, the doctorate precision,

it's there's in there, how much to get up about about about not even, three-one, same, and it's all that's all that's all, that's now

that's being being back, and then, also, we're also, we're trying to to get the

of the the other than in Indonesia. Yeah. So, Ibu, I'm called the gen hunter. Yeah, right? That, you know, to tell, too, what, what, yeah,

what, and, data on the genome sequence for the for the population in Indonesia. That,

what, Thank you, ma'amah. Now, the Lembaqa, Eichmann, is one of a company of the work in the doctorate. Yes. From all, we've already that we've got

different. And then, also, why, why do you know, because, because the language a lot of 719,

the sukuhn't It's a lot of them. We've got to be a barrier, actually, from a certain percumption, in this modern modern, now, now, there's not there's not there's border that. But when I'm starting

this in the Polo Polo that's still that's now like hit, that's it's very that from one the people, with other than other that's different.

The other, the other, but we know that, okay, we're now, we're going to the area of what,

because of the language, it's, look, from, and the time, we've got to now, now,

Now, then, one one of the work of the work in the United Ekman, is to do you make a survey to look, to see mutasimutas mutas to connect.

Why? So, this, talasemia. When we're when we're talasemia, we can't get from literature. We then, then, to design how much the method of diagnostic.

Not got to get. Not. And then, patients also, and they're coming, so patient for talasimia that, if you're going to drug, if you're going to out of the United

to, where, where. I want to Singapore, to America, and the other than the way that's that they're that they're

the case of talasemia, so in therapy with talamiemia. But, not, the not know what notation in

where. So, that we're We're going to be to different populations ethnic and look at what mutations

what's specificly there. From there, we have a petal. Now, this the disease is downed from the two people. So if the two are carrier, then the child, one per that will be the lawymeyre that's the most

the transfuscic. That's very hard for the world, both from the sub-economy, or from the sort of social. So, so, so, we can, we can see specific, mutasiness. So, now, the question is,

If there's a person who's in the other and they're afraid that the first one who's is the first one who's got to get a child to be, we're talking, you're from where? So if he's a person who's whigis, then one other, maybe the sister's the other person, the other than we look at mutation specific bugis, we can look at mutations specific Sunda.

It's usually, that's it's the same we can't make sure what's prenatal diagnosis. And can be done and bejacking. And it's

again with that we're from there we're notary if that this, this it's the that, ethnic

that there, or population we're different this will give us also a different different from different virus that's different from the hostness.

Now, there, and I'm doing and team, did study the whole population in Indonesia. The two-a-a-oh-a-paculate if we're more

more than we're genomic. So we can can't really can't really the about how much

the way the ethnic there's about there's other people that are people who people

people people have been react to be a name's Stephen Johnson syndrome

that is a sort of a very, a very hard, so it's a lot of so that it will be able to leumbung in the hulid and, then, sepsis. Sepsis, that is a infection the whole tubuptu, and it's soly it's really to be takengulangue. That's very, so with genomics in mapping,

we'll give it to be careful. This is aty-atty-aty, this, This is this is sensitive to the number of the different. Yeah. It's more diagnostic, and preventive. Not re-caiase. Bucan.

So, so it's going to that. So, that's from the pharmacogenomicinomic, that's, if if you're given the obadiq, if it's if it's, not overdoses, or if the dosis should be a big, So it's personal medicine, because the the medicine is specific, you know. Yeah. I'm going to talk about the Mesa Dapen.

I'm going to look at the front, Indonesia, since 2004-5, the power of Eichmann, to how, and the pranomics, to how, to do to do, to make majeure the country? We have, We have to the up to the so we're going to be in the

all of the omics, omics. And it's just as well as it's just clear that, now in this just in this in the time 10-bunuch-bunun we have something that that's from manual, from the robotic. In the time of the 10,

that, same as much be competes in the world to get the other so we're so we're in the

in the art, um, and the technology and the the other there's no

there's no doctoran precision to the because we can have a carto, KTP, which isin is the information that's actually that's been done by the other countries that's doing it, so that's all the populations they scan,

survey, and from there, it's from there, he's resistant to what, what's sensitive? Hereditary disease is what? Yeah. So, okay, the most the most of the most of all,

such a lot of, cancer, heart disease, diabetes, lifestyle diseases, that's all can be cagged. Yeah. We've got, we've got, type of what we're like, we're this,

and all of it's all that's from the way of the from the time. I don't know what to like what to the other that's like like that's it like the cutackan's like

you're all this and this is all the much he must be doing to keep all that so. How do? Mapping or what what I'm doing

can can be correlations with the thinking to stunting, diabetes, diabetes, which is very common in Indonesia? Because in the information that there is a lot of information that's

very information that's been a big thing. So, because we know that the paining that's because we know that's not because of the cladineaned Tungal. There's concept, that's there. Conset is that one of a person that's a certain is always complex. the complex, it's all the different different.

So, with genomic, or proteomic, or what other, that we can't really to make the group of the group of the groups. So, diabetes, we know, is in subpoquered by many so again.

It, with itself, can come out, all of it, okay, if they're the type of, the type of, That's light-up, like what's all,

what's what will be in the relationship, with the human being associated. So, we're going to, actually, the next panel. So, three-t-10-pankat-9, information, sequence that not will not be taken total,

is saring back. Then we'll make one panel that's just from information the information that, okay, now, now, take a diabetus, panel, diabetes, what's just. Okay, we'll just know how many, we'll make one that one.

So, so, so we're not a panel for response immune. Because, like, this, That's a lot of people, try to give up, I'm a lot of people who are different, COVID-that-ringed, O-T-G, what's what about the other the three of the mis-sorbiturface-nia, and from the from the huss-nest,

response immune, where, what's that's that's been there? So, we'll needn't have panel just. That's what we're used in practice, yeah. practice. So not, not the whole of what we're going to do. Back to economy. Yeah.

Which is more economic. So, so we can make panels panel that. But, Angeran for Aikman, to the to do what you're going to do what you'd aspirations? Now, one of the

laba of the research that's not, that's not only 100% to get that's bad that's bad from the government. He has also be competencies. He has got to get the other countries which is able to make a jarring

and be collaborating. I'm going to It's very much of how we're the amount of the data that we're per-oleg in here, because, I think that's a little, in in that context that's in that big. In context that big,

but we, from the first we, from the company Eambeckman, that's not ever to be able to be able to work. And so far, can, uh,

the result of the result of the so, so, so, whatever even, even, we've got

we've got to try the out of the But, okay, like, said the time, how long

like, you, you can make, genome, sequence, 270 million

manusia in I think we don't do that. Okay. Okay, not all of all right. We don't. We're trying to do that representing the population. The sample from each of each of them. Statistically.

How many of you, or how rata of hundred thousand people? People, people, It's like 100K, but we don't know how much. For 1,000K is, for 1K just, for 1K is, it's just, now, what's been able to sample? We're just about,

now, it's very, really, it's about, if you're about 3,500. Why Homosome is about the same. But the whole genome sequencing, that we're still 300. So, so many of platforms we're using. The first we're 50K, but it's already

can give them can give an then 2,000, then the 3 million, then the 3 million, so, so, so much, much like we'll we'll take the three million that's after we're going to be used to work

maybe a lot more than just a lot of people after all that's all that's we're just like that's the way that what what is what is thereincering

that's not what that will be given in the report one year because if if there's a technology more efficient and so so much more than, switching to have to

to be able to do that. That's the labagent that's administrative, that what we're doing deliver it, it's like that, and that and there's not going to have any other

There's a lot of other than a newbara. I'm going to COVID-19. Before this, there's a number of SARS. If we look, it's from now, it's not yet what's what what's going to stop in 2003. Yeah, right in October 2002, that's a bit mysterious,

a bit more than a bit more than mutation from SARS. Supposedly. Now, with mysteries, mystery, what you can say what you can say that can give optimism for we can be able to episode that's just much more than this?

I'm from... I'll talk from the the for the for the other than we that we're with the virus

this virus this analysis analysis the information genetick and to look mutation it's

actually to make mitigation. For what mitigation it? that. So, for the pandemic that's the other than

the other can't be used by the people who the biggues that is the most important for that,

why we still do this because we're doing this because we don't We're just who's the most, why we're doing genomic, because we're making for being prepared for if there pandemic in the next time of the

so that we're ready. Now, same, like what's what's actually is being built in Indonesia. The other than the technology the time has been that's avian flu is kind of because not because we're not

so we're not there's a pandemic that's quick this this is the SDM is all all then then and then the capability

diagnostic not there so, so there's So we're not yet. Now, this is true, in my know, it's justro, I think it's a lot

with 100 years of the time of the pandemic influenza. That's right, right. I'm epidemiology. Now, molecular biology.

Yeah. Just to ask, what I'm going to ask, problem is more exponential is the solutions. You as a scientist,

Ibu as a penelite, that's, of, you can, certainly, will be able to make sure to make the next pandemic. Apocas, maybe it's more than 100 years for the pandemic,

for the next? With the scale that we'll look, yeah? Now, it's a bit better, that's now, there's very many of the external that's been able to be able to be able to be able to. The most important is how how much of the environment and the clime.

This is just true something that I don't know if we can control that all or not. Because of our way, we have with the human, the human, the human, too too much, we can't get that

oh yeah, we can't get the pain because there's there's about the bestasances to be different with tuberculosis on the human. Then, the virus corona

on the human not can to a human's because we're different. So we're too, we're going to be a lot of the land. Or even kelelawar, it's a better. The life's not so much, that's not being other, but, but now, with,

I didn't want to let's let's let's have but it's not just, what's what's just what's what's what's, manusia, manolarched malaria to the orangutans. Wow.

The people are not malarion to the manucus not the human, so, monot, moni is, monet is,

monnet, So that's so that's so that's so that's just so that's just so that's that's all that's that's the other than what we're going to be later, there's a pandemic again, we can see see what we're doing

that's what we've done that what we're doing that is what we're on what we've got we've got to get back. Yeah. Yeah. This is very much,

I'm going to end our session with some of the partanan rapid fire, yeah, kind, I'm aga-agged-a-a-bearing. This, I think,

with what, yeah, the research that I'm making inspiration to the young young in Indonesia, learn about science.

I'm optimistic? Is this? Portis of the population in Indonesia who's who are going to be to be more? If I, from from I, I'm optimistic, yeah.

Because I'm now is around, by the people who are people who are people like to look at least the data, um, Bermutu. That,

we can, we can't, I don't see what what there is what what is what is what happened

in the places the places But I'm looking in the environment that's that's got to move. So I'm seeing that's, well, just right now this, many of the good, but now,

now, now, how we can give them to them And they're in a place, or even even in the environment that can make them work work out. Right,

right, there's a lot of that's not just a company, but that's, but that, really, really,

people, don't think about the economy of the their, de, ambilat like that. So, So that he has, what he thinks,

what he's about, the work is, that's how we can't do. How we can't make a sort of milieu that's like that, that's that's in the

question two, Bue, what is the more more than to make making the country Indonesia? Artificial intelligence or synthetic biology?

to make them, yeah? Ah, it's artificial intelligence. Synthetic biology, it's more limited, so, for the fungunaing. It's very limited. ...Casely if we were going to lewetting pagre, yeah. Right, right.

The last, ma'u-four-five, 100 years, Indonesia has already where people in the Nobel in the science? Cobra, we'll see how the Nobel laureate, that's work. Yeah. To get back to that. how they really,

really, bethurted, really, really, it's all of the things for science. Now, now the question is, and also, the tantamance to us, there not, is,

there's, that's the generation ... ... ... And so far, nobler, there's also there's one who's who's one who's who's who's going to be a concept. Because Nobel is concept that can be used universal,

so let's make a sort of a suasana that conducive. Ecosystem. Don't be able to political not even just like

let's be able to make whatever but but communication science is good communication public is because we

can already we've got to the, what's the abuturek the negative, or the negative-notive, being true scientist or that's a comical, so-all-l, not that's all about, not that, this, this, this, not... Nerd-i. Nerd, now, this, if...

Jamin, de, if, now, now, from, what the other, the other people of the studies, We all of all. So I'm all, it's about it. So I'm not too, I'm not too. How much to make sure how much

to make sure and something that's very conducive. And not to get with question, where product you after I gave the data three-torn last? Not be.

We can't. We can't think long-term. We're not. We have to be able to be. not just not just to make not just to but it's an apparent

to the people that not not everything that's not product because that's but it's systemic,

it's systemic, because they're because they're too because they're too five years. Right. So, there's something that's a new.

There's something that's a lot of Yeah. And that's to make them to make sure-termist. But okay, like, let, we're assuming, this, Bu, ecosystem can be facilitation. I'm going to,

I'm going, I'm going, which, who can win in 2004, or before? If you can't, If you're... If you're the answer to be, I'm not. Okay. We'll doackan, like, the best of the best.

No, we're always optimist. I'm optimistic. Because, whatever they're actually them actually, that is something that then, And I'm going to be like that. So, I'm always like that.

So it's something that's very simple. And, but they can't look it, that. Now, how we can see that? Something that's very sadderhanna that is in the front of us, that we don't look at. Because we're not too much. If that, I can't ask one other again.

Or do genetic editing? Genetic editing for- If we're not too sure we can can't know Nobel before in 2004. No. No. I don't. I don't know that we have to

then, make manoeia-manusia that superior with genomic editing. Because the Nobel laureate, that has had a problem. They're not superhuman. Wow.

Thank you. You're welcome. Well, Tere. That's all prof. Prof. Vera, discussion that's very

thank you. This is Endgame.